JW Holdings Corporation (096760.KS) Stock

096760.KS logo

JW Holdings Corporation

096760.KSSouth Korea
Healthcare

Company profile

JW Holdings reported revenue of 969.57 billion KRW for fiscal year 2025, up 9.2% from fiscal year 2024, and net income of 58.50 billion KRW. That is a net profit margin of 6.0% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 243.22 billion KRW, up 1.5% from a year before. Its largest business segment, Medicines, brought in 91% of segment revenue in fiscal year 2024; Korea was the largest region with 98%. In Q1 2026 it reported net income of 20.67 billion KRW, against net income of 10.13 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 928.07 billion KRW in fiscal year 2023 to 969.57 billion KRW in fiscal year 2025, 2.2% a year on average. JW Holdings reports about 114 full-time employees.

What stands out

  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About JW Holdings Corporation

JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecological examining table, sterilizer equipment, diagnostic imaging equipment, operating room equipment, non-PVC film, tube, and empty bag, and health supplements. In addition, the company provides integrated services for IV solution. JW Holdings Corporation was founded in 1945 and is based in Gwacheon-si, South Korea.

Largest shareholders

  • Kyung-Ha Lee28.43 %28.43%
  • Jw Lee Jong Ho Foundation7.47%
  • Jw Holdings Corporation6.40%
  • Ki-Hwan Lee4.646 %4.65%
  • Dong-ha Lee3.02 %3.02%

Share of the company, as of September 25, 2026

Leadership

  • Kyung-Ha Lee — CEO & Chairman of the Board, 62
  • Seongnam Cha — Co-CEO & Internal Director
  • Ji-Woo Choi — CFO & MD
  • Eun-Kyung Ham — Managing Director
  • Na Sook-hee — Internal Director & Head of JW Management Planning Office

How much revenue does JW Holdings make?

JW Holdings reported 969.57 billion KRW in revenue for fiscal year 2025, up 9.2% from 887.71 billion KRW in fiscal year 2024. In Q1 2026 revenue was 243.22 billion KRW.

What is JW Holdings's largest business segment?

Medicines, with 1.08 trillion KRW or 91% of segment revenue in fiscal year 2024. Next: Holding Business (5%) and Other (3%).

Where does JW Holdings make most of its revenue?

Korea: 98% of revenue by region in fiscal year 2024, followed by Asia (1%).

What companies are similar to JW Holdings?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Dong-A ST Co., Ltd. (170900.KS), AprilBio Co.,Ltd. (397030.KQ), HLB Pharmaceutical Co., Ltd. (047920.KQ), Korea United Pharm Inc. (033270.KS).

How has JW Holdings' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 788.94 billion KRW; FY2022, 864.54 billion KRW; FY2023, 928.07 billion KRW; FY2024, 887.71 billion KRW; FY2025, 969.57 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees114
FoundedJan 1, 1945
IPO DateJul 31, 2007
IPO StatusPublic
HeadquartersGwacheon-si, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
JW Gwacheon Tower, Gwacheon-si, 13840
Phone
82 2 8406 777
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “JW Holdings Corporation (096760.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/096760.KS

LinkedInLinkedInXXYouTubeYouTube